Zach Rector to XRP Holders: I’d Be Happy to See This By End of the Year
Crypto commentator Zach Rector recently captured the XRP army’s attention with a bold and optimistic post. He wrote, “I’d be happy to see this by EOY,” referencing an analysis from ChartNerd stating that $5-$8 is inevitable for XRP.
A Repeating Structure Across Cycles
The chart covers XRP’s full price history from 2014 to the present, plotted on a logarithmic scale. ChartNerd identifies a repeating structural pattern across multiple market cycles.
Each cycle follows the same sequence. XRP forms a falling wedge, marked by converging trendlines drawn in red. The price then breaks upward sharply, shown by large green highlighted regions on the chart. After each breakout, the price pulls back and enters another consolidation phase before the next leg higher.
The chart also shows that multiple falling wedges are contained within long-term symmetrical triangles, adding to the bullish narrative.
Where the Current Cycle Stands
ChartNerd’s analysis shows another cycle underway. XRP’s most recent breakout was the climb of over 500% in late 2024. That move pushed XRP above the symmetrical triangle. The asset is now retesting the top of the symmetrical triangle and sitting close to the apex of another falling wedge.
For the breakout, the chart marks a 1.618 Fibonacci extension level. This places the projected target at $8.80. The green-highlighted region on the right side of the chart projects price movement into 2027, suggesting the move could take time to develop fully. A key support channel drawn in blue dashed lines has held across the chart’s history, rising consistently from the 2014 lows.
The current price chart sits at approximately $1.51, placing the $5-$8 target roughly 230%-430% above current levels.
The Community Pushes Back
Responses to the analysis varied widely. Some agreed with the bullish outlook. One commenter said the price would go much higher than the $5-$8 target. Others pushed back. One commenter said he had never seen any of those prices, reminding the community that XRP has never hit $4. Another said he would be happy just to see $3.
ChartNerd has previously set targets as high as $27, but he expects XRP to reach that level by 2030.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
